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Abstract: Patients with uterine leiomyosarcoma (LMS) typically present with vaginal bleeding, pain, and a pelvic mass. 
Typical presentations with hypercalcemia or eosinophilia have been reported. Radiographic evaluation with combined 
positron emission tomography/computed tomography may assist in the diagnosis and surveillance of women with uterine 
LMS. A recently developed risk-assessment index is highly predictive of disease-speciﬁ  c survival. Ovarian preservation 
does not appear to negatively impact outcome, and the addition of adjuvant therapy after surgical treatment does not seem 
to improve survival. It is noteworthy that LMP2-deﬁ  cient mice exhibit spontaneous development of uterine LMS with a 
disease prevalence of ∼37% by 12 months of age. The LMP2 gene is transcribed from a promoter containing an interferon 
(IFN)-γ-response factor element; thus, the IFN-γ-signal strongly induces LMP2 expression. Furthermore, a recent report 
demonstrated the loss of ability to induce LMP2 expression, which is an interferon (IFN)-γ-inducible factor, in human 
uterine LMS tissues and cell lines. Analysis of human uterine LMS shows somatic mutations in the IFN-γ signalling path-
way, thus the loss of LMP2 induction is attributable to a defect in the earliest steps of the IFN-γ signalling pathway. The 
discovery of an impaired key cell-signalling pathway may provide new targets for diagnostic approaches and therapeutic 
intervention.
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Introduction
Smooth muscle tumors (SMTs) have been traditionally divided into benign leiomyomas (LMA) and 
malignant leiomyosarcomas (LMS) based on cytological atypia, mitotic activity and other criteria. 
Uterine LMS, which are some of the most common neoplasms of the female genital tract, are relatively 
rare SMTs, having an estimated annual incidence of 0.64 per 100,000 women (Zaloudek and Hendrickson, 
2002). They account for approximately one-third of uterine sarcomas, and are considered to be aggres-
sive malignancies with a ﬁ  ve-year survival rate of only 53% for tumors conﬁ  ned to the uterus (Gadducci 
et al. 1996; Nordal and Thoresen, 1997). Gynecological cancer, for instance breast cancer and endo-
metrial carcinomas, are strongly promoted by female hormones, but the rate of hormone receptor 
expression is reported to be signiﬁ  cantly less in human uterine LMS compared with normal USM cells. 
These low receptor expressions were found to not correlate with the promotion of initial disease devel-
opment or with the overall survival of patients with uterine LMS; however, molecular targeting thera-
pies against tumors have recently shown remarkable achievements (Leitao et al. 2004; Perez et al. 2004). 
It is noteworthy that, when adjusting for stage and mitotic count, LMS has a signiﬁ  cantly worse prog-
nosis than carcinosarcoma (Miettinen and Fetsch, 2006). As uterine LMS is resistant to chemotherapy 
and radiotherapy, and thus surgical intervention is virtually the only means of treatment for this disease 
(Brooks et al. 2004; Dusenbery et al. 2005; Wu et al. 2006), developing an efﬁ  cient adjuvant therapy 
is expected to improve the prognosis of the disease. A trend towards prolonged disease-free survival is 
seen in patients with matrix metalloproteinase (MMP)-2-negative tumors (Bodner-Adler et al. 2004). 
Although typical presentations with hypercalcemia or eosinophilia have been reported, this clinical 
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abnormality is not an initial risk factor for uterine 
LMS. LMP2 knockout mice exhibit a defect in 
proteasome function, and LMP2
-/- female mice are 
shown to develop uterine leiomyosarcomas, with 
a disease prevalence of 36% by 12 months of age 
(Van Kaer et al. 1994; Hayashi and Faustman, 
2002). Furthermore, a recent report showed that 
the loss of LMP2 expression in human LMS tissues 
is probably attributable to a defect in the earliest 
steps of the IFN-γ-signalling pathway. Defective 
LMP2 expression may initiate the development of 
spontaneous human uterine LMS (Hayashi and 
Faustman, 2002; Hayashi et al. 2006). Because 
there is no effective therapy for unresectable uter-
ine LMS, these ﬁ  ndings may enable the develop-
ment of diagnostics and specific molecular 
therapies to treat this disease.
LMP2-Deﬁ  cient Mice Exhibit 
Spontaneous Development 
of Uterine LMS
Although gynecological cancers, for instance, 
breast cancer and endometrial carcinomas, are 
stongly promoted by female hormones, the rate of 
hormone receptor expression is reported to be 
signiﬁ  cantly less in uterine LMS than in normal 
uterine smooth muscle (USM). As apoptotic 
mechanisms have also been implicated in many 
human cancers, investigating the dysregulation of 
the expression of apoptotic and/or cell-cycle 
regulators in uterine LMS is required to identify 
molecular pathways that could possibly be impor-
tant in the development of human uterine LMS. 
Although the signiﬁ  cant differential expression of 
apoptotic and cell-cycle regulatory factors, includ-
ing initiation factor, in human uterine LMS have 
all been reported and compared to normal USM, 
there exists no scientiﬁ  c evidence to show that 
abnormal expression of these factors directly cor-
relates to the initiation and promotion of uterine 
LMS (Zhai et al. 1999; Miyajima et al. 2001; 
Raspollini et al. 2005; Alhopuro P. et al. 2005; 
Leiser et al. 2005; Anderson et al. 2006).
The targeted disruption of LMP2 results in the 
impairment of tissue- and substrate-dependent 
proteasome function (Van Kaer et al. 1994). 
LMP2
-/- mice were reported to be prone to the 
development of uterine neoplasms (Hayashi and 
Faustman, 2002). The percentage of mice with 
overt tumors increased with age after six months, 
with a cumulative prevalence of disease in female 
mice of 37% by 12 months of age and no apparent 
plateau at this late observation time. LMS was 
observed in LMP2
-/- female mice but not in their 
parental mice, C57BL/6 mice (Hayashi and 
Faustman, 2002) (Fig. 1). Histological examina-
tions of LMP2
-/- uterine neoplasms revealed com-
mon characteristic abnormalities of uterine LMS 
(Fig. 1). The tumors lacked lymphoid inﬁ  ltrates, 
which is a sign of immune recognition, and con-
sisted of uniform elongated USM cells arranged 
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Figure 1. Development of uterine neoplasms in LMP2
-/- mice. Uterine neoplasms in LMP2
-/- mice. a and e, abdominal cavities of female 
C57BL/6 (a) and LMP2
-/- (e) mice, showing a uterine tumor (outlined by yellow arrowheads) in the latter. b and f, female genital organs of 
C57BL/6 (b) and LMP2
-/- (f) mice, showing a uterine neoplasm in the latter. c, d, g, h, histologycal analysis showing the normal smooth 
muscle cells of the uterus of C67BL/6 mice (c and d) and the abnormal cells of a leiomyosarcoma of the uterus of LMP2
-/- mice (g and h). 
c,g, × 200; d,h, × 400.299
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into bundles. The nuclei of the tumor cells varied 
in size and shape; furthermore, mitosis was fre-
quent. In contrast, USM cells of C57BL/6 mice 
were normal in appearance, and relatively few 
Ki-67-positive cells, the proliferating cells of solid 
tumors, were observed in the basal cell layer of 
normal USM, whereas most basal cells vividly 
expressed Ki-67 in LMP2
-/- mice (Hayashi and 
Faustman, 2002). These histopathological studies 
indicate the abnormal proliferation of LMP2
-/- 
USM cells in the basal cell layer of normal USM. 
In LMP2
-/- mice, proteasomal activity against 
hydrophobic and basic substrates but not acidic 
substrates was lower in the muscle. Furthermore, 
ﬂ  ow cytometric analysis showed no difference in 
the expression of MHC class I molecules. Impor-
tantly, spontaneous uterine LMS was particularly 
detected, but no other tumor progression was 
observed at high/low incidences in both male and 
female LMP2
-/- mice; therefore, LMP2 expression, 
rather than providing an escape from immune 
surveillance, seems to play an important role in the 
spontaneous development of uterus LMS.
Correlation Between Defective 
LMP2 Expression and Human 
Uterine LMS
Several reports suggest that INF-γ-induced restora-
tion of antigen-processing machinery improves 
anti-tumor-speciﬁ  c antigen CTL recognition in 
some patients; thus, approaches to activate this 
pathway may be of beneﬁ  t to patients with LMP2 
deﬁ  ciency. Furthermore, it should be demonstrated 
whether human uterine LMS shows a weak expres-
sion of LMP2. The effects of IFN-γ on LMP2 
expression was examined using ﬁ  ve cell lines 
(Hayashi et al. 2006). LMP2 expression were not 
markedly induced by IFN-γ treatment in human 
uterine LMS cell lines, although cervical epithelial 
adenocarcinoma cell lines and normal human 
uterus smooth muscle cells underwent strong 
induction of LMP2 following IFN-γ treatment 
(Hayashi et al. 2006). Furthermore, the experi-
ments, performed separately at several medical 
facilities, revealed a serious loss in the ability to 
induce LMP2 expression in human uterine LMS 
tissues in comparison with normal USM tissues 
located in same tissue sections: normal total, 
26 cases; LMA total, 24 cases; LMS total, 32 cases 
(Hayashi et al. 2006). In addition, immunohisto-
chemistry showed marked LMP2 expression in 
cervical epithelial adenocarcinoma tissues as well 
as cell lines treated with IFN-γ.
The defect was localized to Janus-activated kinase 
1 (JAK1) activation, which acts upstream in the 
IFN-γ signal pathway since IFN-γ treatment could 
not strongly induce JAK1 kinase activity in human 
uterine LMS cell lines. Sequence analysis demon-
strated that the loss of IFN-γ responsiveness in the 
human uterine LMS cell line was attributable to 
the inadequate kinase activity of JAK1 due to a 
G781E mutation in the ATP-binding region 
(Hayashi et al. 2006).
Mutations in IFN-γ Signalling 
Pathway in Human LMS Tissues
IFN-γ treatment markedly increased the expression 
of LMP2, a subunit of the proteasome, which alters 
the proteolytic speciﬁ  city of proteasomes. After 
binding of IFN-γ to the type II IFN receptor, JAK1 
and JAK2 are activated and phosphorylate the 
signal transducer and activator of transcription 
1(STAT1) on the tyrosine residue at position 701 
(Tyr701) and the serine residue at position 727 
(Ser727) (Parmar and Platanias, 2005; Platanias, 
2005) (Fig. 2). The phosphorylated STAT1 forms 
homodimers that translocate to the nucleus and 
bind GAS (IFN-γ-activated site) elements in the 
promoters of IFN-γ-regulated genes (Parmar and 
Platanias, 2005; Platanias, 2005) (Fig. 2).
Genetic alterations in tyrosine kinases have 
previously been ﬁ  rmly implicated in tumorgenesis, 
but only a few serine/threonine kinases are known 
to be mutated in human cancers (Futreal et al. 2004; 
Jones and Baylin, 2007; Lengyel et al. 2007; 
Pajares et al. 2007). For instance, mice carring 
homozygous deletion of Pten alleles developed 
widespread smooth muscle cell hyperplasia and 
abdominal leiomyosarcomas (Hernando et al. 
2007), and JUN oncogene ampliﬁ  cation and over-
expression block adipocytic differentiation in 
highly aggressive sarcomas (Mariani et al. 2007). 
Most frequently, leiomyosarcomas have appeared 
in the uterus, retroperitoneum or extremities, and 
although histologically indistinguishable, they 
have different clinical courses and chemotherapeu-
tic responses. The molecular basis for these differ-
ences remains unclear. Therefore, the examination 
of human uterine LMS tissues (32 LMS tissue 
sections and normal tissue sections located in the 
same tissue) was performed to detect somatic 
(tumor-speciﬁ  c) mutations in the IFN-γ signal 300
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cascade. The genetic approach has already 
addressed that somatic mutations in JAK1 mole-
cule correlate to the initiation of several cancer 
progressions and other disorders (Briscoe et al. 
1996; Rossi et al. 2005; Haan et al. 2008). Overall, 
nearly 42.9% (6/14) of uterine LMS tissues had 
mutations in the ATP-binding region or kinase-
active site of JAK1. Furthermore the genetic 
approach has already revealed that somatic muta-
tions in the LMP2 molecule or its enhancer region 
correlate to the initiation of several cancer progres-
sions and other disorders (Heward et al. 1999; 
Satoh et al. 2006; Krämer et al. 2007; Liu et al. 
2007; Mehta et al. 2007), 35.7% (5/14) of uterine 
LMS tissues had somatic mutations in the 
Lmp2 promoter region, which is required for 
transcriptional activation. In addition, genetic 
examination has already demonstrated that somatic 
mutations in the STAT1 molecule correlate to the 
initiation of several disorders (Dupuis et al. 2001; 
Dupuis et al. 2003; Chapgier et al. 2006; Scarzello 
et al. 2007). Nearly 35.7% (5/14) of uterine LMS 
tissues had mutations in the STAT1 intermolecular 
region. Although the genetic approach has already 
addressed that marked JAK2 activation causes 
myelo- and lymphoproliferative disease (Baxter 
et al. 2005; Campbell et al. 2005; James et al. 2005; 
Kralovics et al. 2005; Tefferi et al. 2005), no 
somatic mutation in the ATP-binding region and 
kinase-active site of JAK2 was detected in uterine 
LMS. In a recent report, high-resolution genome-
wide array comparative genomic hybrodization 
Figure 2. The interferon-γ signaling pathway and mutations in its components found in human uterine leiomyosarcoma. After binding of 
interferon-γ (IFN-γ) to the type II IFN receptor, Janus activated kinase 1 (JAK1) and JAK2 are activated and phosphorylate STAT1 (signal 
transducer and activator of transcription 1) on the tyrosine residue at position 701 (Tyr701). The tyrosine-phosphorylated form of STAT1 
forms homodimers that translocate to the nucleus and bind GAS (IFN-γ-activated site) elements, which are present in the promoters of 
IFN-γ-regulated genes. The IFN-γ-activated JAKs also regulate, through as-yet-unknown intermediates, activation of the catalytic subunit 
(p110) of phosphatidylinositol 3-kinase (PI3K). The activation of PI3K ultimately results in downstream activation of protein kinase C-δ 
(PKC-δ), which in turm regulates phosphorylation of STAT1 on the serine residue at position 727 (Ser727). The phosphorylation of Ser727 
is not essential for the translocation of STAT1 to the nucleus or for the binding of STAT1 to DNA, but it is required for full transcriptional 
activation. IFNGR1, IFN-γ receptor subunit 1; IFNGR2, IFN-γ receptor subunit 2. Investigation of human uterine LMS tissues (total of 14 cases 
of LMS tissue sections and normal tissue sections located in same tissue) for somatic mutations in the IFN-γ signal cascade, JAK1, JAK2, 
STAT1 and Lmp2 promoter region.301
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(CGH) analysis of LMS cases gave gene-level 
information about the ampliﬁ  ed and deleted regions 
that may play a role in the development and pro-
gression of human uterine LMS. Among the most 
intriguing genes, whose copy number sequence 
was revealed by CGH, were loss of JAK1 
(1p31∼p32) and LMP2 (6p21.3) (Lee et al. 2006; 
Svarvar et al. 2006). The discovery of these muta-
tional defects in a key cell-signalling pathway may 
be an important development in the pathogenesis 
of human uterine LMS.
It is probable that the list of new elements 
involved in IFNs-mediated signalling will continue 
to grow during the next few years, whereas the 
contributions of known pathways might need to be 
re-evaluated. At present, it seems that the activation 
of more than one signalling pathway is required 
for the generation of different biological properties 
of IFNs, and no signalling cascade alone is sufﬁ  -
cient for the generation of any given biological 
end-point. For example, the biological functions 
of the STAT-, NF-κB and p38 signalling pathways 
are required for antiviral effects or anti-tumor 
effects of IFNs, but activation of these pathways 
alone is not sufﬁ  cient to elicit an antiviral or anti-
tumor response (Ramana et al. 2002; Sizemore 
et al. 2004). Such a requirement for multiple sig-
nalling pathways also seems to be the case for 
IFNs-dependent anti-proliferative responses, and 
might reﬂ  ect the synergistics effects of various 
signals at the levels of gene transcription and 
translation; therefore, additional genetic analysis 
is required to completely elucidate the mutational 
activation of a key cell-signalling pathway in 
human uterine LMS.
Potential Role of Anti-Oncogenic 
Function by LMP2
The growth of cell lines with JAK1 kinase activity 
is strongly inhibited by IFN-γ treatment, whereas 
the growth of JAK1-deﬁ  cient cell lines is unaf-
fected (Sexl et al. 2003). Similarly, the cell cycle 
distribution pattern of freshly explanted tumor cells 
derived from Jak1-deficient tumors shows no 
response to IFN-γ treatment (Sexl et al. 2003). The 
growth of the original SKN cells, which had defec-
tive JAK1 activity, was unaffected by IFN-γ treat-
ment (population doubling time (PDT) = 15.2 hrs) 
(Hayashi et al. 2006). In contrast, the growth of 
JAK1-transfected SKN cells, which had strong 
exogenous JAK1 activity, was prevented by IFN-γ 
treatment (PDT = 18.1 hrs). Interestingly, analysis 
of LMP2-transfected SKN cells showed that exog-
enous LMP2 expression resulted in cell growth 
arrest (PDT = 17.9 hrs) (Hayashi et al. 2006). 
Conversely, the growth of LMP2-transfected SKN 
cells was unaffected by IFN-γ treatment 
(PDT = 18.0 hrs). In SKN-Lmp2 transfectants, 
there is a correlation between the levels of exog-
enous LMP2 expression and the degree of suppres-
sion of the transformed phenotype. The biological 
function of LMP2 with revertant-inducing activity 
on SKN cells has been demonstrated.
Microarray analysis provides insight into the 
gene expression changes associated with malignant 
transformation. To investigate whether stable 
LMP2 expression contributes to cell growth phe-
notype in SKN cells, the experiment (using 
Affymetrix human GeneChip HG U133 Plus2.0) 
demonstrated the expression proﬁ  le of SKN cells 
transfected with plasmid without insert (pCEP9) 
compared with LMP2 coding DNA (pCEP9-
LMP2). Microarray analysis has elucidated that 
LMP2 expression dramatically influences the 
expression pattern of cell-cycle regulators, espe-
cially anti-oncogenic factor interferon regulatory 
factor 1 (IRF-1), which directly correlate to pro-
gressively worsen with the increasing stage and 
grade of the tumor (Fig. 3).
The down-regulation of MHC expression, 
including the lmp2 gene, is one of the biological 
mechanisms that tumor cells use to evade host 
immune surveillance (Swann and Smyth, 2007). 
Recently, the incidence of IFN-γ unresponsiveness 
in human tumors was examined in several cancers, 
and revealed that around 33% of each group exhib-
ited a reduction in IFN-γ sensitivity (Kaplan et al. 
1998). Nevertheless, LMP2 expression, rather than 
providing an escape from immune surveillance, 
seems to play an important role in the negative 
regulation of uterine LMS cell growth. Defective 
LMP2 expression is likely to be a risk factor for 
the development of human uterine LMS, as it is in 
LMP2-deﬁ  cient mice.
Conclusion
To improve the prognosis of human uterine LMS, 
research experiments were performed to identify 
the key role of pro- or anti-oncogenic factors that 
have an important function in their pathogenesis 
and that could serve as molecular targets for tumor 
treatment. For this purpose, several research 302
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facilities conducted a microarray procedure 
between human uterine LMS and normal USM and 
showed that several known pro-oncogenic factors, 
such as brain-speciﬁ  c polypeptide PEP-19 and 
c-kit, may be associated with the pathogenesis of 
human uterine LMS (Kanamori et al. 2003; Wang 
et al. 2003; Ylisaukko-oja et al. 2006). However, 
in terms of the tumorgenesis of human uterine LMS, 
merely comparing the expression of potential pro-
oncogenic factors between normal and malignant 
tissues is not sufﬁ  cient because the results obtained 
may be the consequence of malignant transforma-
tion and, therefore, not necessarily the cause.
For almost all types of cancer studied to date, 
it seems as if the transition from a normal, healthy 
cell to a cancer cell is a step-wise progression that 
requires genetic changes in several different onco-
genes and tumor suppressors. In order to generate 
a cancer cell, a series of mutations must occur in 
the same cell. Since the likelihood of any gene 
becoming mutated is very low, it stands to reason 
that the chance of several different mutations 
occuring in the same cell is highly unlikely. For 
this reason, cells in an elderly body have had more 
time to accumulate the changes needed to form 
cancer cells, whereas those in a child are much less 
likely to have acquired the requisite genetic 
changes. Importantly, clinical studies have revealed 
loss of the ability to induce LMP2 expression in 
human uterine LMS tissues in comparison with 
normal USM tissues. The discovery of somatic 
mutational defects in the IFN-γ-signalling pathway 
may be important for the initial development of 
uterine LMS. It is noteworthy that stable LMP2 
expression contributes to cell proliferation, which 
directly correlates to the progressive deterioration 
with increasing stage and grade of the tumor. 
Recent advances in our understanding of the biol-
ogy of uterine LMS have concentrated on the 
impaired IFN-γ signalling pathway. It is clear that 
mutations in key regulatory genes (tumor suppres-
sors and proto-oncogenes) alter the behavior of 
cells and can potentially lead to the unregulated 
growth seen in cancer. Therefore, continued 
improvement of our knowledge of the molecular 
biology of uterine LMS may ultimately lead to 
novel therapies and improved outcome.
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